Compare ResMed Inc. (RMD) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Synchrony Financial — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: ResMed Inc. is the larger of the two by market cap, and Synchrony Financial pays the higher dividend (1.84%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Synchrony Financial for 29 Days on average.
| RMD | SYF | |
|---|---|---|
Market Cap | $31.89B | $23.99B |
Volume | 618,314 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $275.96 | $88.47 |
52-Week Low | $182.82 | $63.78 |
Typical Hold Time | 51 Days | 29 Days |
Enterprise Value | $31.24B | $24.23B |
Dividend Yield | 1.16% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Synchrony Financial (SYF) trades at $73.72, up 2.49% on the day, with a bullish technical signal despite some bearish moving average indicators. The stock shows strong fundamentals with a low P/E of 7.56, robust net income margin of 23.4%, and consistent earnings beats in recent quarters. Recent developments include a partnership with OpenAI to enhance AI-driven shopping and expansion of CareCredit's veterinary financing via Vetspire, signaling growth initiatives.
The outlook remains positive given attractive valuation, high profitability, and analyst consensus price target of $87.58 implying ~19% upside. Key risks include rising credit delinquencies industry-wide and volatile cash flow trends, with net cash flow turning negative in 2026. Institutional sentiment is bullish with 61% buy ratings, but investors should monitor consumer spending resilience and Q3 2026 earnings due October 20.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
